Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast Enhanced Ultrasound and Elastography of the Neonatal Brain
NCT05648812Phase 3Recruiting
- Sponsor
- Turku University Hospital
- Start
- Jan 2024
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sulfur hexafluoride in hypoxic-ischemic encephalopathy (HIE), stroke and neonatal encephalopathy (NE) (4 arms), sponsored by Turku University Hospital. Primary endpoint: Qualitative and quantitative assessment of neonatal brain perfusion at 20 days. Started Jan 2024; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
hypoxic-ischemic encephalopathy (HIE)strokeneonatal encephalopathy (NE)
Beyond the preview
Go deeper on NCT05648812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648812.